Search clinical trials for: PCI-32765 (Ibrutinib)

Total 2808 results

Steven E. Coutre
National Cancer Institute (NCI)

Terminated

Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Pharmacyclics LLC.

Completed

Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients

Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | CCND1 Positive | CCND2 Positive | CCND3 Positive | CD20 Positive | Refractory Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Israel
Kami Maddocks, MD
Pharmacyclics LLC.

Active, not recruiting

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent... and other conditions

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (VEGA)

Lymphoma, Mantle-Cell

Taiwan, Thailand, Malaysia, India, Puerto Rico, Spain, Turkey, Czechia, Brazil, Greece, Poland, Sweden, Romania
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Janssen, LP

Completed

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

CD20 Positive | Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal... and other conditions

United States
Assistance Publique - Hôpitaux de Paris
Biofire

Completed

Results of FilmArray® Gastro-intestinal Panel and Serum Procalcitonin in Acute Colitis and Infectious Diarrhea in the ER (PRODIARRAY)

Acute Diarrhea | Acute Colitis of Presumed Infectious Origin

France
Christian Buske
Amgen; Janssen, LP

Recruiting

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1)

Waldenstrom Macroglobulinemia

Austria, Germany, Greece
TG Therapeutics, Inc.

Completed

Ublituximab + Ibrutinib in Select B-cell Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia

United States
Charite University, Berlin, Germany

Completed

Impact of Real-time Angiographic Co-registered OCT on PCI Results - the OPTICO-integration II Study (Integration-II)

Ischaemic Heart Disease

Germany
Maatschap Cardiologie Zwolle
Abbott; Radboudumc Technology Center; Clinical Studies

Recruiting

Use of Physiology to Evaluate Procedural Result After PCI CTO (ULTRA-CTO)

Percutaneous Coronary Revascularisation | Complex Coronary Lesion

Netherlands
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults

Healthy

Belgium
Johnson & Johnson Private Limited

Completed

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

India
Janssen Research & Development, LLC

Completed

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

Healthy

United States
Oncternal Therapeutics, Inc
University of California, San Diego; Pharmacyclics LLC.; California Institute...

Active, not recruiting

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
ZOLL Circulation, Inc., USA

Completed

COOL AMI EU Pilot Trial to Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction

Acute Myocardial Infarction

Slovenia, Poland, Austria, Estonia, Hungary, Serbia, Sweden, United Kingdom
Duke University
Food and Drug Administration (FDA); Medtronic; Abbott Medical Devices; The Medicines... and other collaborators

Terminated

SAFE-PCI for Women (SAFE-PCI)

Percutaneous Coronary Intervention | Ischemic Symptoms
The Lymphoma Academic Research Organisation
Janssen Pharmaceutica N.V., Belgium

Terminated

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas (BIBLOS)

B-cell Lymphoma

France, Belgium
Unity Health Toronto

Unknown

Revascularization Strategies for STEMI; The CMR Endpoint Study (ASSIST-CMR)

Acute Myocardial Infarction

Canada
Heinrich-Heine University, Duesseldorf
Philips Medical Systems

Unknown

PCI Suite: Road Map Fusion Imaging in Coronary Diagnostics and Therapy (PCI Suite)

Coronary Disease

Germany
General Hospital of Ningxia Medical University

Unknown

HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer

Carcinoma, Small Cell Lung

China
Pharmacyclics Switzerland GmbH
Janssen Biotech, Inc., including Johnson & Johnson

Enrolling by invitation

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Solid Tumor | Leukemia, B-cell | Graft Vs Host Disease

United States, Spain, Taiwan, United Kingdom, Australia, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, France, Turkey, Czechia, Hungary, Poland, Sweden
Janssen-Cilag Ltd.

Completed

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice (FIRE)

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

France
The Lymphoma Academic Research Organisation

Completed

Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma (iLOC)

Intraocular Lymphoma | Primary Central Nervous Lymphoma

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program

Chronic Lymphocytic Leukemia

Italy
Janssen-Cilag S.p.A.

Completed

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting (EVIdeNCE)

Leukemia, Lymphocytic, Chronic, B-Cell

Italy
The First Affiliated Hospital with Nanjing Medical...
Xian-Janssen Pharmaceutical Ltd.

Unknown

Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Göteborg University
Sahlgrenska University Hospital, Sweden

Withdrawn

Quality of Life and Target Achievement After Treatment of Patients With Stable Angina Pectoris (LOBSTR)

Stable Angina Pectoris

Sweden
Second Affiliated Hospital, School of Medicine,...
Shanghai Chest Hospital; Second Affiliated Hospital of Wenzhou Medical University and other collaborators

Not yet recruiting

Long-term Clinical Outcomes of intraVascular Ultrasound-guided vs Angiography-guided Primary pErcutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction (LOVEinSTEMI)

ST Elevation Myocardial Infarction

China
Yonsei University

Completed

Optical CoherenCe Tomography-gUided Coronary Intervention in Patients With Complex lesIons: a Randomized Controlled Trial (OCCUPI Trial)

Coronary Artery Disease

Korea, Republic of
University Hospital Inselspital, Berne

Terminated

Optical Coherence Tomography to Improve Outcome for Coronary Revascularisation Using Bioresorbable Vascular Scaffolds (OPTICO-BVS)

Coronary Occlusion

Switzerland
University of Limerick

Unknown

The Use Of FFR Guided PCI Versus Complete Revascularization and Treatment Of Infarct Related Artery Only In Patients With STEMI (FAIO)

STEMI | Multivessel Coronary Artery Disease | FFR Guided PCI

Ireland
Shenzhen Raysight Intelligent Medical Technology...
Shanghai Zhongshan Hospital; West China Hospital; Shenzhen People's Hospital

Not yet recruiting

Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)

Myocardial Ischemia | Cardiovascular Diseases | Coronary Artery Disease | Coronary Disease | Arteriosclerosis | Vascular Disease Occlusive

China
CoreAalst BV

Recruiting

Precise Procedural and PCI Plan (P4) (P4)

Coronary Artery Disease

Denmark, United Kingdom, Belgium, Italy, Hungary
IRCCS San Raffaele

Recruiting

Real World Data on Ibrutinib Use in PCNSL Rel/Ref (ReWIPretro)

PCNSL

Italy
Memorial Sloan Kettering Cancer Center
Ohio State University; Pharmacyclics LLC.; Janssen Biotech, Inc.

Completed

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

T-cell Lymphoma | Relapsed and Refractory T-cell Lymphoma

United States
University of Cologne

Completed

Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) (IRENO)

Nodular Lymphocyte-Predominant Hodgkin's Lymphoma

Germany
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center; Pharmacyclics LLC.

Terminated

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

Follicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIa

United States
Janssen Biotech, Inc.
Pharmacyclics LLC.

Approved for marketing

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Relapsed or Refractory Mantle Cell Lymphoma

United States, Brazil, Puerto Rico
Aarhus University Hospital Skejby
Abbott

Active, not recruiting

The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER) (OCTOBER)

Ischemic Heart Disease | Ischaemic Heart Disease

Denmark, United Kingdom, Sweden, Finland, Germany, Belgium, Norway, Poland, Netherlands, Estonia, Ireland, Italy, Latvia
Harbin Medical University

Not yet recruiting

Study on the Improvement of Myocardial Microcirculation After Acute Anterior Myocardial Infarction

Intravascular Imaging and Microvascular Obstruction
Seung-Jung Park
CardioVascular Research Foundation, Korea

Recruiting

Fractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease (FATE-MAIN)

Coronary Artery Disease | Coronary Artery Disease Left Main

Korea, Republic of
Helios Health Institute GmbH
Heart Center Leipzig - University Hospital

Recruiting

Remote Ischemic Conditioning With Local Ischemic Postconditioning in High-Risk ST-elevation Myocardial Infarction (RIP-HIGH)

ST Elevation Myocardial Infarction

Austria, Germany
University of Zurich

Recruiting

Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial (TAVI-PCI)

Coronary Artery Disease | Aortic Stenosis | PCI | TAVI

Switzerland
Odense University Hospital

Active, not recruiting

Coronary Artery Healing and Bioresorbable Scaffold (HONEST)

Myocardial Infarction | Coronary Artery Disease

Denmark
Russian Academy of Medical Sciences

Completed

The Comparative Effectiveness of Hybrid Revascularization (MIDCAB Then PCI) With DES Versus Multivessel DES PCI or CABG (HREVS)

Myocardial Ischemia | Heart Diseases | Coronary Artery Disease | Coronary Disease

Russian Federation
Aarhus University Hospital Skejby
Terumo Europe N.V.; Johnson & Johnson

Completed

SORT-OUT V - Randomised Clinical Comparative Study of the Nobori and the Cypher Stent. (SORT-OUT V)

Coronary Artery Disease | Angina Pectoris

Denmark
Catholic University of the Sacred Heart

Unknown

FFR or OCT Guidance to RevasculariZe Intermediate Coronary Stenosis Using Angioplasty (FORZA)

Ischemic Heart Disease

Italy
Grupo de Investigación Clínica en Oncología Radioterapia

Completed

Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)

Small Cell Lung Carcinoma

Spain

Search clinical trials for: PCI-32765 (Ibrutinib)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations